National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Liposomal irinotecan (Onivyde®) is indicated for the treatment of metastatic adenocarcinoma of the pancreas, in combination with 5-fluorouracil and leucovorin in adult patients who have progressed following gemcitabine based therapy.

Rapid Review

Commenced Completed Outcome
13/06/2017 13/07/2017 Full Pharmacoeconomic Evaluation Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.